Company Oncofocus S.r.l. with Fiscal Code 39781403
recorded a turnover of 2024 of
78.661,
with a net profit of
65.694
and having an average number of employees of
1.
The company operates in the field of Activităţi de asistenţă medicală specializată having the NACE code 8622.
Sales - Ron
Sales, Profit, Employees, Total Income, Financial Results -
Oncofocus S.r.l.
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
Sales - EUR
-
-
-
11.789
46.773
40.996
51.364
47.627
59.822
78.661
Total Income - EUR
-
-
-
11.789
46.827
41.076
51.479
49.411
61.131
82.412
Total Expenses - EUR
-
-
-
263
1.235
1.933
2.549
2.722
13.315
6.376
Gross Profit/Loss - EUR
-
-
-
11.526
45.593
39.143
48.930
46.688
47.816
76.035
Net Profit/Loss - EUR
-
-
-
11.172
44.188
38.168
47.682
45.839
47.298
65.694
Employees
-
-
-
0
0
0
0
1
1
1
The table presents the most important indicators of the company from the Profit and Loss Account for the last 10 years of activity as found at the Ministry of Finance. The data provides the evolution of the company during this period regarding the increases and possibly decreases recorded.
In the last year of activity, the sales increased by 32.2%, from 59.822 euro in the year 2023, to 78.661 euro in 2024.
The Net Profit increased by 18.660 euro, from 47.298 euro in 2023, to 65.694 in the last year.
Check the financial reports for the company - Oncofocus S.r.l.
Financial Rating - ONCOFOCUS S.R.L.
See the company's note based on the submitted financial data, relative to the industry of which it is a part.
Financial Rating
Payment Limits - Oncofocus S.r.l.
See the company's payment capacity for situations in which you conclude contracts with payment terms.
Check Payment Limits
Prob. of insolvency - Oncofocus S.r.l.
It determines the risk of insolvency based on the submitted accounting balance.
Insolvency Probability
Financial Reports - Oncofocus S.r.l.
Check all the financial reports of the company and know the risks in collaboration with it.
Check Financial Reports
Financial Analysis Reports provide a clear and comprehensive view of a company's financial activity. In addition to presenting financial data, the reports analyze this data so that any user can understand whether the results are positive or less favorable. The Financial Rating provides an analysis based on the most important financial ratios, including liquidity, solvency, and profitability. Payment Limits represent the maximum amounts for which a company can offer goods or services on credit to its clients. The Probability of Insolvency presents the theoretical probability that a company may not be able to meet its financial obligations towards its creditors, i.e., suppliers and financial institutions.
The table presents the company's Balance Sheet structure for the last 10 years. Current Assets recorded a value of
102.826 euro in 2024 which includes Inventories of
0 euro, Receivables of
44.469 euro and cash availability of
58.357 euro.
The company's Equity was valued at
78.562 euro, while total Liabilities amounted to
25.127 euro.
Equity increased by 21.991 euro, from 56.888 euro in 2023, to 78.562 in 2024.
The Debt Ratio was 24.2% in the year 2024.
Similar services useful for checking companies and business development.
SellNet
Get the contact details for any company and get in touch with it.
Sectoral Studies
Knows the market and develops its own development strategies according to sectorial data.
Databases
Export in excel files the data of the companies selected according to the desired criteria.
Import - Export
Find importers and exporters according to the type of activity and the countries in which they carry it out.
Similar services represent services associated with companies that allow for a better analysis of clients and suppliers. Company Contacts help you get in touch with the desired companies. Sector Studies provide an overview of an industry, the most important competitors, and the geographical distribution of companies. Company Lists allow you to attract new clients, while Import-Export services give you access to companies engaged in such activities.
Comments - Oncofocus S.r.l.